A Modular Approach to Light Capture and Synthetic Tuning of the Excited-State Properties of Fe(II)-Based Chromophores.

The development of chromophores based on earth-abundant transition metals whose photophysical properties are dominated by their charge-transfer excited states has inspired considerable research over the past decade. One challenge associated with this effort is satisfying the dual requirements of a strong ligand field and chemical tunability of the compound's absorptive cross-section. Herein we explore one possible approach using a heteroleptic compositional motif that combines both of these attributes into a single compound. With the parent complex [Fe(phen)3]2+ (1; where phen is 1,10-phenanthroline) as the starting material, replacement of one of the phen ligands for two cyanides to obtain Fe(phen)2(CN)2 (2) allows for conversion to [Fe(phen)2(C4H10N4)]2+ (3), a six-coordinate Fe(II) complex whose coordination sphere consists of two chelating polypyridyl ligands and one bidentate carbene-based donor. Ground-state absorption spectra of all three compounds exhibit 1A1 → 1MLCT transition(s) associated with the phen ligands that are relatively insensitive to the identity of the third counterligand(s). Ultrafast time-resolved electronic absorption measurements revealed lifetimes for the MLCT excited states of compounds 1 and 2 of 180 ± 30 and 250 ± 90 fs, respectively, values that are typical for iron(II)-based polypyridyl complexes. The corresponding kinetics for compound 3 were substantially slower at 7.4 ± 0.9 ps; the spectral evolution associated with these dynamics confirms that these kinetics are tracking the MLCT excited state and, more importantly, are coupled to ground-state recovery from this excited state. The data are interpreted in terms of a modulation of the relative energies of the MLCT and ligand-field states across the series, leading to a systematic destabilization of metal-localized ligand-field excited states such that the low-energy portions of the charge-transfer and ligand-field manifolds are at or near an energetic inversion point in compound 3. We believe these results illustrate the potential for a modular, orthogonal approach to chromophore design in which part of the coordination sphere can be targeted for light absorption while another can be used to tune electronic-state energetics.

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.

CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or safety. We further evaluated daratumumab's effects on immune cells in whole blood samples of relapsed/refractory MM patients from both treatment arms of the phase 3 POLLUX study (lenalidomide/dexamethasone [Rd] or daratumumab plus Rd [D-Rd]) at baseline (D-Rd, 40; Rd, 45) and after 2 months on treatment (D-Rd, 31; Rd, 33) using cytometry by time-of-flight. We confirmed previous reports of NK cell reduction with D-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep responders to D-Rd, with a higher proportion of CD8+ versus CD4+ T cells. The expansion of CD8+ T cells correlated with clonality, indicating generation of adaptive immune response with D-Rd. D-Rd resulted in a higher proportion of effector memory T cells versus Rd. D-Rd reduced immunosuppressive CD38+ regulatory T cells. This study confirms daratumumab's immunomodulatory MOA in combination with immunomodulatory drugs and provides further insight into immune cell changes and activation status following daratumumab-based therapy.